ArticleAlzheimer's research & therapy2026
Plasma EV LINE-1 mRNA as a diagnostic biomarker for differentiating Alzheimer's disease from non-Alzheimer's dementias.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Alzheimer’s disease (AD) is the most common form of dementia. However, there is a lack of effective diagnostic biomarkers to differentiate AD from non-Alzheimer’s (Non-AD) dementias, such as vascular dementia, Lewy body dementia, Parkinson’s disease dementia, and chronic traumatic encephalopathy. This study aims to evaluate the expression variations of LINE-1 retrotransposon in plasma EVs as a potential biomarker to differentiate between AD and Non-AD dementias and explore its diagnostic value in clinical practice. Here, we analyzed two independent clinical cohorts: a training cohort (AD: n = 139; Non-AD: n = 137; Control: n = 79) and a validation cohort (AD: n = 158; Non-AD: n = 133; Control: n = 61). Expression of LINE-1 mRNA in plasma EVs, containing ORF1, ORF2, and 5’UTR regions, was quantified using RT-qPCR, and the differences between control, AD and Non-AD groups were assessed by one-way ANOVA or non-parametric tests. In both training and validation cohorts, LINE-1 mRNA expression was significantly higher in AD patients compared to Non-AD patients and healthy control in the ORF1, 5’UTR, and ORF2 regions. LINE-1 expression was correlated with that of neuroinflammatory and neurodegeneration markers (GFAP and NfL), whereas no significant correlations were revealed between LINE-1 expression and cognitive scores. ROC analysis revealed that while LINE-1 was less effective than traditional biomarkers for general AD diagnosis, it demonstrated superior accuracy in differentiating AD from Non-AD dementias. Specifically, the AUC values for LINE-1_ORF2 and LINE-1_5’UTR were 0.91 and 0.92, respectively, significantly outperforming p-Tau217 (AUC = 0.80) and GFAP (AUC = 0.62) in the training cohort. Multivariate regression confirmed that the LINE-1 composite index was an independent predictor of AD. These findings suggest that the LINE-1 composite score, as an age-independent predictor, holds significant clinical potential for the differential diagnosis of AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.